One Comprehensive Universal Radiotherapy for Everyone (1-CURE)

The ARPA‑H 1‑CURE solicitation (ARPA‑H‑SOL‑26‑147) seeks proposals that develop therapeutic solutions aligned with the program’s Target Product Profile (TPP) guidelines. Offerors must submit a complete proposal package—including a detailed technical narrative, budget, timeline, and supporting materials—through SAM.gov, with a minimum 120‑day validity period. Core requirements are: (1) a TPP for each selected therapeutic area (TA) that meets or exceeds the minimum specifications; (2) a Novelty and Intellectual Property (IP) disclosure section that documents any prior government submissions, existing funding decisions, background and foreground IP (with a table matching the Commercialization Plan), and asserts government rights; (3) consultant disclosures covering other organizational affiliations, positions, and participation in foreign government talent‑recruitment programs; (4) a Capability statement describing relevant experience, facilities, biosafety certifications, and any Government‑furnished assets; (5) a Commercialization Plan outlining market opportunity, competitive landscape, IP ownership, and prospective partners; (6) a risk analysis with high‑level mitigation strategies; and (7) a Task Description Document (TDD) that breaks down tasks by TA, links them to milestones and 1‑CURE metrics, and contains no proprietary information. Proposals must also identify any formal teaming agreements, provide a basis‑of‑estimate, and include optional prime organization logo. Compliance with these elements is essential for evaluation, feedback, and award under the 1‑CURE program.

Notice ID

9ab23f65e4ed4406831a74a3daba0279

Solicitation Number

ARPA-H-SOL-26-147

NAICS Code

541714

Classification Code

AN13